HK Stock Market Move | HENLIUS (02696) rose nearly 4% as the commercialization of the targeted therapy drugs BILDYOS and TUZEMTY in Canada began.

date
10:18 24/06/2026
avatar
GMT Eight
Fosun Pharma (02696) rose nearly 4%, as of the time of writing, it rose by 3.98% to HK $65.05, with a turnover of HK $1050.57 million.
HENLIUS (02696) rose nearly 4% at the time of writing, up 3.98% to HK$65.05, with a turnover of HK$10.57 million. On the news front, on June 23, according to HENLIUS official WeChat account, the company announced a commercial launch in Canada for Denosumab Injection (60 mg/mL) BILDYOS and Denosumab Injection (120 mg/1.7 mL) TUZEMTY, covering all approved indications of the original drugs PROLIA and XGEVA in Canada. Denosumab is used for various indications, enhancing bone strength for the treatment of osteoporosis and tumor-related bone events. BILDYOS's launch in Canada further expands treatment options for Canadian patients and helps reduce healthcare costs by increasing access to biosimilars. These two products further enrich Organon's expanding portfolio of biosimilar products in Canada, covering five major therapeutic areas, including cancer, with several products on the market for over nine years.